Neogenomics, Inc.
NEO
$16.06
$0.221.36%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 766.30M | 745.97M | 727.33M | 709.16M | 689.19M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 766.30M | 745.97M | 727.33M | 709.16M | 689.19M |
| Cost of Revenue | 429.76M | 424.46M | 413.44M | 401.36M | 386.95M |
| Gross Profit | 336.53M | 321.51M | 313.89M | 307.81M | 302.24M |
| SG&A Expenses | 353.25M | 358.18M | 357.32M | 355.26M | 349.59M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 821.18M | 819.07M | 807.84M | 792.48M | 771.39M |
| Operating Income | -54.89M | -73.10M | -80.51M | -83.32M | -82.20M |
| Income Before Tax | -54.55M | -102.19M | -110.27M | -113.99M | -105.45M |
| Income Tax Expenses | -2.67M | -2.98M | -2.24M | -522.00K | -1.41M |
| Earnings from Continuing Operations | -51.88 | -99.21 | -108.03 | -113.47 | -104.04 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -51.88M | -99.21M | -108.03M | -113.47M | -104.04M |
| EBIT | -54.89M | -73.10M | -80.51M | -83.32M | -82.20M |
| EBITDA | 10.89M | -6.59M | -12.67M | -13.70M | -11.03M |
| EPS Basic | -0.40 | -0.77 | -0.84 | -0.89 | -0.82 |
| Normalized Basic EPS | -0.25 | -0.34 | -0.37 | -0.37 | -0.36 |
| EPS Diluted | -0.40 | -0.77 | -0.84 | -0.89 | -0.82 |
| Normalized Diluted EPS | -0.25 | -0.34 | -0.37 | -0.37 | -0.36 |
| Average Basic Shares Outstanding | 515.86M | 514.18M | 512.39M | 510.90M | 509.44M |
| Average Diluted Shares Outstanding | 517.06M | 514.18M | 512.39M | 510.90M | 509.44M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |